review · The Egyptian Heart Journal

Efficacy and safety of tafolecimab a new PCSK9 inhibitor in patients with hyperlipidemia: a systematic review and meta-analysis of randomized controlled trials

Ali Ashraf Salah Ahmed
Abdelrahman Mahmoud
Hazem Mohamed Salamah
Ahmad Alkheder
Mohamed Hassan
Toka Ahmed Ashour
Mohamed R. Abdelraouf
Diaa Hakim

2025Open accessAlexandria University

Abstract

Tafolecimab is a valuable treatment option for hyperlipidemia, which showed improvement in several lipid indices (LDL, LDL-C, LDL CFB, non-HDL-C CFB, and apolipoprotein B CFB). However, it increased the rates of injection site reactions.

Research topics

Lipoproteins and Cardiovascular Health
Pharmaceutical Economics and Policy

Sustainable Development Goals

3Good Health and Well-being

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

View on publisher site Record on OpenAlex

DOI: 10.1186/s43044-025-00653-z

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.

New to MARATTO™? Create a free account.